Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 355,262,336
  • Shares Outstanding, K 2,693,830
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.78
  • Price/Sales 4.98
  • Price/Cash Flow 16.07
  • Price/Book 5.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.48 +1.07%
on 07/11/17
137.08 -3.79%
on 07/20/17
-4.55 (-3.34%)
since 06/23/17
3-Month
122.34 +7.80%
on 05/11/17
137.08 -3.79%
on 07/20/17
+8.45 (+6.85%)
since 04/25/17
52-Week
109.32 +20.64%
on 12/07/16
137.08 -3.79%
on 07/20/17
+6.99 (+5.60%)
since 07/25/16

Most Recent Stories

More News
Report: More than 15,000 Adverse Events Linked to Xarelto in 2016

As the number of lawsuits against the blood thinner Xarelto continues to climb, so do reports of injuries and deaths caused by the controversial anticoagulant, according to a recent study by the Institute...

BAYRY : 130.0100 (-0.13%)
JNJ : 131.88 (-0.85%)
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

JNJ : 131.88 (-0.85%)
ABBV : 72.52 (-1.88%)
AMGN : 180.89 (-0.09%)
BIIB : 282.96 (-0.61%)
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 131.88 (-0.85%)
LLY : 82.19 (-3.01%)
VRTX : 161.97 (-2.49%)
NVS : 84.20 (-0.11%)
GILD : 73.74 (-0.87%)
GSK : 41.96 (-0.66%)
BIIB : 282.96 (-0.61%)
What's in the Cards for Geron (GERN) this Earnings Season?

Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

JNJ : 131.88 (-0.85%)
VRTX : 161.97 (-2.49%)
ARNA : 24.35 (+0.04%)
GERN : 2.89 (+0.35%)
Stock Market News for July 25, 2017

Benchmarks turned in mixed performances on Monday.

NFLX : 186.97 (-0.50%)
HIBB : 14.15 (+8.02%)
GOOGL : 969.03 (-2.93%)
AAPL : 152.74 (+0.43%)
JNJ : 131.88 (-0.85%)
MRK : 62.36 (-0.34%)
CLB : 100.21 (-5.73%)
FB : 165.28 (-0.43%)
AMZN : 1,039.87 (+0.09%)
Dermatological Drugs Market Forecast 2017-2027

LONDON, July 25, 2017 /PRNewswire/ --

JNJ : 131.88 (-0.85%)
Dermatological Drugs Market Forecast 2017-2027

Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma....

JNJ : 131.88 (-0.85%)
Bioengineered Protein Drugs Market Worth US$336.9 Billion by 2025: Increasing Drugs in Phase III of Clinical Trials to Boost the Market

Some of the prominent participants in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy's Laboratories...

BAYRY : 130.0100 (-0.13%)
ABT : 50.83 (+0.06%)
JNJ : 131.88 (-0.85%)
MRK : 62.36 (-0.34%)
LLY : 82.19 (-3.01%)
NVS : 84.20 (-0.11%)
AMGN : 180.89 (-0.09%)
Accelerator Corporation Announces Series A Financing in Rodeo Therapeutics to Focus on Small-Molecule Regenerative Therapies

Accelerator Corporation, a leading life science investment and management firm, today announced a $5.9 million Series A financing in Rodeo Therapeutics Corporation, a company developing...

JNJ : 131.88 (-0.85%)
LLY : 82.19 (-3.01%)
CGIX : 3.75 (-1.32%)
Markets Right Now: Stocks end mostly lower, except for tech

NEW YORK (AP) — The latest on developments in financial markets (All times local):

JNJ : 131.88 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 134.79
1st Resistance Point 133.34
Last Price 131.88
1st Support Level 130.94
2nd Support Level 129.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.